免疫检查点TIGIT在肺癌免疫治疗中的研究进展  

Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy

作　　者：吴洁琼 任敦强[1] 毕焕焕 易冰倩 王红梅[1] Jieqiong WU;Dunqiang REN;Huanhuan BI;Bingqian YI;Hongmei WANG(Department of Respiratory and Critical Care Medcine,The Affiliated Hospital of Qingdao University;School of Medicine Qingdao University,Qingdao 266000,China)

机构地区：[1]青岛大学附属医院呼吸与危重症医学科,青岛266000 [2]青岛大学医学部

出　　处：《中国肺癌杂志》2022年第11期819-827,共9页Chinese Journal of Lung Cancer

基　　金：吴阶平医学基金会临床科研专项资助基金项目(No.320.6750.19094-29)资助。

摘　　要：T细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域(T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain,TIGIT)是近年新发现的免疫检查点分子,主要表达于T细胞及自然杀伤(natural killer,NK)细胞表面。通过与白细胞分化抗原155(cluster of differentiation 155,CD155)等配体结合,抑制T细胞及NK细胞介导的免疫反应影响肿瘤微环境。多项临床前研究已经证实,TIGIT/CD155通路可在多种实体肿瘤和血液系统肿瘤中发挥作用。目前研究TIGIT抑制剂单药或联合程序性死亡受体1(programmed cell death 1,PD-1)/程序性死亡受体-配体1(programmed cell death ligand 1,PD-L1)抑制剂治疗肺癌的临床试验正在进行中。T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain(TIGIT)is a newly discovered immune checkpoint molecule,mainly expressed on the surface of T cells and natural killer(NK)cells.By binding to cluster of differentiation 155(CD155)and other ligands,it inhibits T cell and NK cell-mediated immune responses and affects the tumor microenvironment.Multiple preclinical studies have demonstrated that the TIGIT/CD155 pathway plays a role in a variety of solid and hematological tumors.Clinical trials investigating TIGIT inhibitors alone or in combination with programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)inhibitors for lung cancer are currently underway.

关 键 词：TIGIT PD-L1 免疫治疗 肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]